Joseph Bast, MD
Nephrology · Omaha, NENPI 1124287131
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.4% of the total across 157 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 11.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,083, more than ten times the $120 reported in 2019.
Across 157 payments — averaging $30.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$531
- Vantive US Healthcare LLC$444
- Nxstage Medical, Inc.$409
- Bard Peripheral Vascular, Inc.$383
- Medtronic$338
- ANI Pharmaceuticals, Inc.$320
- plus $2K from 23 others
What the payments were for
- Food & beverage$4,67396%
- Education$1774%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 14 | $531 |
| Vantive US Healthcare LLC | 7 | $444 |
| Nxstage Medical, Inc. | 9 | $409 |
| Bard Peripheral Vascular, Inc. | 4 | $383 |
| Medtronic | 3 | $338 |
| ANI Pharmaceuticals, Inc. | 20 | $320 |
| Bayer | 11 | $261 |
| Mallinckrodt Hospital Products Inc. | 3 | $241 |
| Baxter Healthcare | 3 | $196 |
| Vifor Pharma, Inc. | 8 | $177 |
| Abbott | 2 | $169 |
| Scpharmaceuticals Inc. | 3 | $154 |
| Novartis | 8 | $150 |
| Amgen | 7 | $141 |
| Boehringer Ingelheim | 7 | $135 |
| Travere Therapeutics, Inc. | 15 | $132 |
| Otsuka America Pharmaceutical, Inc. | 6 | $102 |
| Ardelyx, Inc. | 4 | $88 |
| Calliditas Therapeutics US Inc. | 3 | $70 |
| GSK | 4 | $68 |
| Lilly USA, LLC | 3 | $64 |
| Edwards Lifesciences | 1 | $64 |
| Fresenius USA Marketing, Inc. | 4 | $63 |
| Novo Nordisk | 2 | $42 |
| Mozarc Medical US LLC | 2 | $40 |
| Sanofi | 1 | $25 |
| Lexicon Pharmaceuticals, Inc. | 1 | $16 |
| Ascendis Pharma Endocrinology Inc | 1 | $13 |
| Boston Scientific | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SYMPLICITY G3$333
- NXSTAGE SYSTEM ONE$240
- Pristine$153
- CARDIOMEMS$145
- Renal - Chronic$128
- LOKELMA$125
- Kerendia$122
- FUROSCIX$120
- PUREFLOW SL$115
- ACTHAR$114
- PURIFIED CORTROPHIN GEL$111
- Renal - PD$111
How this compares
$4,850 in reported general payments places this provider in the 85th percentile of 60 nephrology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JynarqueTolvaptan | 13 | $256,767 |
| FarxigaDapagliflozin Propanediol | 55 | $43,792 |
| AuryxiaFerric Citrate | 17 | $28,694 |
| JardianceEmpagliflozin | 22 | $14,223 |
| Cinacalcet Hcl | 31 | $11,613 |
| Sevelamer Carbonate | 41 | $8,515 |
| Torsemide | 269 | $5,703 |
| Midodrine Hcl | 30 | $3,501 |
| Potassium Chloride | 123 | $3,242 |
| Potassium Citrate ErPotassium Citrate | 27 | $3,189 |
| Nifedipine ErNifedipine | 117 | $3,150 |
| Calcitriol | 102 | $1,949 |
| Calcium Acetate | 28 | $1,802 |
| Doxazosin Mesylate | 64 | $1,393 |
| Clonidine | 14 | $1,150 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Jynarque | $102 | $256,76713 claims |
| AstraZenecaFarxiga | $531 | $43,79255 claims |
| Boehringer IngelheimJardiance | $135 | $14,22322 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $320 | $87342 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 60 nephrology providers in Nebraska.
Other nephrology in Omaha
- Richard LundOmaha$378K
- Jeffrey PasserOmaha$146K
- Roslyn MannonOmaha$64K
- Troy PlumbOmaha$17K
- Eric MagliuloOmaha$9K
- Prasanth RavipatiOmaha$7K
- Stefan HemmingsOmaha$5K
- Sunil JagadeshOmaha$4K
- Judd BauerOmaha$3K
- Mohammed NazmulOmaha$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.